Feinstein Institutes to research novel radiation countermeasure
January 21, 2025, 3:05PMNuclear News

The Feinstein Institutes’ Ping Wang (from left), Max Brenner, and Asha Jacob Varghese will lead a study on treating radiation sickness using the human hormone ghrelin. (Photo: Feinstein Institutes).
The Feinstein Institutes for Medical Research, home of the research institutes of New York’s Northwell Health, announced it has received a five-year, $2.9 million grant from the National Institutes of Health to investigate the potential of human ghrelin, a naturally occurring hormone, as a medical countermeasure against radiation-induced gastrointestinal syndrome (GI-ARS).
Tags:
Share: